These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 16740585)

  • 41. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark.
    Olsen J; Jepsen MR
    Int J Technol Assess Health Care; 2010 Apr; 26(2):183-91. PubMed ID: 20392322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
    Mahoney MC
    J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ; Kobus KE; Diaz M; O'Shea M; Van Minh H; Goldie SJ
    Vaccine; 2008 Jul; 26(32):4015-24. PubMed ID: 18602731
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccines for human papillomavirus infection: a critical analysis.
    Nath AK; Thappa DM
    Indian J Dermatol Venereol Leprol; 2009; 75(3):245-53; quiz 254. PubMed ID: 19439876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
    Paavonen J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S3-9. PubMed ID: 18162244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
    Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
    Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.
    Colantonio L; Gómez JA; Demarteau N; Standaert B; Pichón-Rivière A; Augustovski F
    Vaccine; 2009 Sep; 27(40):5519-29. PubMed ID: 19616499
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study.
    Favato G; Baio G; Capone A; Marcellusi A; Costa S; Garganese G; Picardo M; Drummond M; Jonsson B; Scambia G; Zweifel P; Mennini FS
    Med Care; 2012 Dec; 50(12):1076-85. PubMed ID: 22922435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccination as a prevention strategy for human papillomavirus-related diseases.
    Kahn JA
    J Adolesc Health; 2005 Dec; 37(6 Suppl):S10-6. PubMed ID: 16310136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
    Wong G; Howard K; Webster A; Chapman JR; Craig JC
    Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
    de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
    Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of optimal control in assessing the most cost-effective implementation of a vaccination programme: HPV as a case study.
    Brown VL; Jane White KA
    Math Biosci; 2011 Jun; 231(2):126-34. PubMed ID: 21377481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human papillomavirus vaccines in development: if they're successful in clinical trials, how will they be implemented?
    Shaw AR
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S246-8. PubMed ID: 16213009
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
    Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
    Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Vaccines against human papillomavirus (HPV); between registration and implementation].
    van Rossum TG; de Melker HE; Houweling H; Voordouw AC; Meijer CJ; Helmerhorst TJ; Kretzschmar M; Berkhof J; van der Noordaa J
    Ned Tijdschr Geneeskd; 2008 Apr; 152(17):987-92. PubMed ID: 18549172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human papillomavirus vaccine and men: what are the obstacles and challenges?
    Stupiansky NW; Alexander AB; Zimet GD
    Curr Opin Infect Dis; 2012 Feb; 25(1):86-91. PubMed ID: 22143118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.
    Isidean SD; Tota JE; Gagnon JA; Franco EL
    Expert Rev Vaccines; 2015 Jan; 14(1):119-33. PubMed ID: 25266065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.